CareRx Enterprise Value Over E B I T D A from 2010 to 2024

CRRX Stock  CAD 1.90  0.13  7.34%   
CareRx Corp Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to grow to 7.38 this year. During the period from 2010 to 2024, CareRx Corp Enterprise Value Over EBITDA quarterly data regression pattern had sample variance of  10,489 and median of  12.52. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
7.03122833
Current Value
7.38
Quarterly Volatility
102.4179994
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CareRx Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CareRx Corp's main balance sheet or income statement drivers, such as Interest Expense of 10.5 M, Selling General Administrative of 28.8 M or Other Operating Expenses of 381.7 M, as well as many indicators such as Price To Sales Ratio of 0.24, Dividend Yield of 0.0 or PTB Ratio of 1.08. CareRx financial statements analysis is a perfect complement when working with CareRx Corp Valuation or Volatility modules.
  
This module can also supplement various CareRx Corp Technical models . Check out the analysis of CareRx Corp Correlation against competitors.

Other Information on Investing in CareRx Stock

CareRx Corp financial ratios help investors to determine whether CareRx Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CareRx with respect to the benefits of owning CareRx Corp security.